Drugs / Dalargin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07404358 | May 2025 → Jul 2026 overdue | multiple organ dysfunction syndrome | Botkin Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dalargin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07404358 ↗ |
| Action | Activate | “opioid receptor agonist” NCT07404358 ↗ |
| Modality | Peptide | “synthetic analog of the endogenous opioid peptide leucine-enkephalin” NCT07404358 ↗ |
| Route | Intravenous | “continious intravenous infusion” NCT07404358 ↗ |